According to Nuvama, the increased competitive intensity following this approval is negative for Cipla, as it raises the risk to market share and peak sales expectations for its Advair inhaler ...

The shares of Cipla dropped nearly 2 percent to its day's high on January 13 after the US FDA granted its final approval to rival Aurobindo Pharma for a generic version of the GSK's Advair inhalers.

LONDON (Reuters) - GlaxoSmithKline's new CEO Emma Walmsley, who takes over on April 1, has won a short-term reprieve from the threat of generic Advair with a delay in U.S. approval for Mylan's copy of ...

1. Wixela Inhub is Mylan’s generic version of Advair, an asthma treatment made by GlaxoSmithKline. 2. Tosymra is a sumatriptan nasal spray used to treat migraines in adults. 3. Imbruvica in ...

LONDON, March 29 (Reuters) - GlaxoSmithKline shares gained on Wednesday as lack of news about U.S. approval of a generic copy of its blockbuster inhaled lung drug Advair buoyed speculation that a ...

From Nov. 17, Viatris will be the surviving company formed by the combination of leading generic maker Mylan and Upjohn, Pfizer's generics business. The new entity will continue to focus on the prior ...